FindTrial
Sign In

AGN-151586

DRUG10 trials

Sponsors

Allergan, AbbVie

Conditions

Forehead LinesGlabellar LinesModerate to Severe Glabellar Lines

Phase 1

A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
CompletedNCT05496335
AbbVieGlabellar Lines
Start: 2022-08-30End: 2023-05-30Updated: 2026-06-26
Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines
CompletedNCT06151561
AbbVieModerate to Severe Glabellar Lines
Start: 2024-01-05End: 2024-04-03Updated: 2026-06-26
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
CompletedNCT06834789
AbbVieGlabellar Lines
Start: 2025-02-18End: 2025-11-03Updated: 2025-11-17
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines
RecruitingNCT07756580
AbbVieGlabellar Lines
Start: 2026-08-10End: 2027-03-01Target: 120Updated: 2026-09-09

Phase 2

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
CompletedNCT04096326
AllerganGlabellar Lines
Start: 2019-09-26End: 2020-09-09Updated: 2023-07-28
A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants
RecruitingNCT07730554
AbbVieForehead Lines
Start: 2026-07-22End: 2026-11-01Target: 80Updated: 2026-08-21

Phase 3

A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
CompletedNCT05248893
AbbVieGlabellar Lines
Start: 2022-02-25End: 2023-06-26Updated: 2024-05-29
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
CompletedNCT05248867
AbbVieGlabellar Lines
Start: 2022-03-16End: 2023-03-17Updated: 2024-05-24
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
CompletedNCT05248880
AbbVieGlabellar Lines
Start: 2022-03-08End: 2023-02-01Updated: 2026-02-18
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
CompletedNCT06308198
AbbVieGlabellar Lines
Start: 2024-03-29End: 2025-02-26Updated: 2026-06-26